SI2119726T2 - Novi in močni MHC peptidi razreda II, pridobljeni iz survivina in neurokana - Google Patents
Novi in močni MHC peptidi razreda II, pridobljeni iz survivina in neurokana Download PDFInfo
- Publication number
- SI2119726T2 SI2119726T2 SI200831406T SI200831406T SI2119726T2 SI 2119726 T2 SI2119726 T2 SI 2119726T2 SI 200831406 T SI200831406 T SI 200831406T SI 200831406 T SI200831406 T SI 200831406T SI 2119726 T2 SI2119726 T2 SI 2119726T2
- Authority
- SI
- Slovenia
- Prior art keywords
- peptide
- cancer
- nucleic acid
- tumors
- cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 23
- 102000000763 Survivin Human genes 0.000 title claims abstract 4
- 108010002687 Survivin Proteins 0.000 title claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 4
- 108010043296 Neurocan Proteins 0.000 title 1
- 102100030466 Neurocan core protein Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims abstract 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract 8
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 8
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 229960005486 vaccine Drugs 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 2
- 239000013604 expression vector Substances 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000008361 ganglioneuroma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000008228 Ependymoblastoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 206010014968 Ependymoma malignant Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000004066 Ganglioglioma Diseases 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000005649 gangliocytoma Diseases 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 206010073131 oligoastrocytoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 206010035059 pineocytoma Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
- Novi in močni MHC peptidi razreda II, pridobljeni iz survivina in neurokana ZAHTEVKI1. Peptid, ki ga sestavlja aminokislina z zaporedjem SEQ ID št. 1 (TLGEFLKLDRERAKN).
- 2. Peptid v skladu z zahtevkom 1, pri čemer ima navedeni peptid z zaporedjem SEQ ID št. 1 zmožnost vezave na molekulo HL A alela HL A-DR.
- 3. Peptid v skladu z zahtevkom 2, pri čemer lahko navedeni peptid stimulira T-celice CD4 aliCD8.
- 4. Fuzijski protein, sestavljen iz peptida v skladu s katerim koli od zahtevkov 1 do 3, pripojen na N-terminalne aminokisline HLA-DR z antigenom povezane invariantne verige (Ii).
- 5. Nukleinska kislina, ki kodira peptid v skladu s katerim koli od zahtevkov 1 do 4 ali ekspresijski vektor, ki izraža navedeno nukleinsko kislino.
- 6. Peptid v skladu s katerim koli od zahtevkov 1 do 4 ali nukleinska kislina ali ekspresijski vektor v skladu z zahtevkom 5 za uporabo v medicini.
- 7. Gostiteljska celica, sestavljena iz nukleinske kisline ali ekspresijskega vektorja v skladu z zahtevkom 5, pri čemer je zaželeno, da je gostiteljska celica antigen-predstavitvena celica, zlasti dendritična celica ali antigen-predstavitvena celica.
- 8. Metoda izdelave peptida v skladu s katerim koli od zahtevkov 1 do 4, metoda, sestavljena iz kultiviranja gostiteljske celice v skladu z zahtevkom 7, ki izraža nukleinsko kislino ali ekspresijski vektor v skladu z zahtevkom 5, in izolira peptid od gostiteljske celice ali gojišča.
- 9. Peptid v skladu s katerim koli od zahtevkov 1 do 4, nukleinska kislina ali ekspresijski vektor v skladu z zahtevkom 5, ali celica v skladu z zahtevkom 7 za uporabo pri zdravljenju raka, najbolje v obliki cepiva.
- 10. Peptid za uporabo v skladu z zahtevkom 9, pri čemer je navedeni rak izbran iz pilocitičnega astrocitoma, disembrioplastičnega nevroepitelijskega tumorja, oligodendroglioma, ependimoma, multiformnega glioblastoma, mešanih gliomov, oligoastrocitomov, meduloblastomov, retinoblastomov, nevroblastomov, germinomov, teratomov, gangliogliomov, gangliocitomov, centralnih gangliocitomov, primitivnih nevroektodermalnih tumorjev (PNET, npr. meduloblastom, meduloepiteliom, nevroblastom, retinoblastom, ependimoblastom), tumorji epifiznega parenhima (npr. pineocitom, pineoblastom), tumorji ependimskih celic, tumorji horoidnega pleteža, nevroepitelijski tumorji negotovega izvora (npr. cerebralna gliomatoza, astroblastom), glioblastom, tumor prostate, rak na dojki, ezofagealni rak, rak kolona, kolorektalni rak, karcinom ledvičnih celic, svetiocelični karcinom ledvičnih celic, pljučni rak, OŽS, rak jajčnikov, melanom, rak trebušne slinavke, ploščatocelični karcinom, levkemija in meduloblastom in drugi tumorji ali raki, ki kažejo čezmerno ekspresijo survivina.
- 11. Peptid, ki se uporablja v skladu z zahtevkom 10 ali 11 v kombinaciji z vsaj enim peptidom, izbranih iz skupine, sestavljene iz št. zaporedja SEQ ID 4 do 13 za zdravljenje ledvičnega raka ali v kombinaciji z vsaj enim peptidom, izbranim iz skupine, sestavljene iz št. zaporedja SEQ ID 4, 8,11,12 in 15 do 23 za zdravljenje raka kolona.
- 12. Komplet, ki ga sestavlja: (a) vsebnik, ki vsebuje farmacevtski sestavek, sestavljen iz peptide v skladu s katerim koli od zahtevkov 1 do 4, nukleinske kisline ali ekspresijskega vektorja v skladu z zahtevkom 5, ali celica v skladu z zahtevkom 7 v obliki raztopine ali v liofilizirani obliki; (b) kot možnost še drugi vsebnik, ki vsebuje vehikel ali raztopino za rekonstitucijo za liofilizirano formulacijo; (c) kot možnost vsaj en peptid, izbran iz skupine, ki je sestavljena iz št. zaporedja SEQ ID 4 do 23, in (d) kot možnost navodila za uporabo raztopine in/ali rekonstituciji in/ali uporabo liofilizirane formulacije.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008944.4A EP2119726B2 (en) | 2008-05-14 | 2008-05-14 | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI2119726T1 SI2119726T1 (sl) | 2015-05-29 |
| SI2119726T2 true SI2119726T2 (sl) | 2018-03-30 |
Family
ID=39789337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831406T SI2119726T2 (sl) | 2008-05-14 | 2008-05-14 | Novi in močni MHC peptidi razreda II, pridobljeni iz survivina in neurokana |
| SI200931275T SI2291395T2 (sl) | 2008-05-14 | 2009-05-14 | Nov in močan razred peptidov mhc ii, izpeljan iz survivina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931275T SI2291395T2 (sl) | 2008-05-14 | 2009-05-14 | Nov in močan razred peptidov mhc ii, izpeljan iz survivina |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US8647629B2 (sl) |
| EP (3) | EP2119726B2 (sl) |
| JP (1) | JP5663473B2 (sl) |
| KR (2) | KR101602024B1 (sl) |
| CN (1) | CN102027006B (sl) |
| AU (1) | AU2009248413B2 (sl) |
| BR (2) | BR122019014468B8 (sl) |
| CA (1) | CA2724198C (sl) |
| CY (2) | CY1115999T1 (sl) |
| DK (2) | DK2119726T5 (sl) |
| EA (1) | EA019603B1 (sl) |
| ES (2) | ES2532896T5 (sl) |
| HK (2) | HK1156323A1 (sl) |
| HR (2) | HRP20150300T4 (sl) |
| HU (2) | HUE024541T2 (sl) |
| MX (1) | MX2010012443A (sl) |
| NO (1) | NO2119726T3 (sl) |
| NZ (1) | NZ588605A (sl) |
| PL (2) | PL2119726T5 (sl) |
| PT (2) | PT2119726E (sl) |
| RS (1) | RS53872B2 (sl) |
| SI (2) | SI2119726T2 (sl) |
| UA (1) | UA103481C2 (sl) |
| WO (1) | WO2009138236A1 (sl) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| DK2567707T3 (en) * | 2007-07-27 | 2017-07-31 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| DE602008000891D1 (de) * | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
| RS53872B2 (sr) | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| WO2011073234A2 (en) | 2009-12-15 | 2011-06-23 | Ascendis Pharma As | Growth hormone composition |
| FR2955112B1 (fr) | 2010-01-14 | 2012-01-20 | Isp Investments Inc | Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| US9109007B2 (en) | 2010-08-18 | 2015-08-18 | Purdue Pharma L.P. | MHC-I restricted epitopes containing non-natural amino acid residues |
| CN103547283A (zh) * | 2010-12-14 | 2014-01-29 | 伊玛提克斯生物技术有限公司 | 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 |
| CN102181401B (zh) * | 2011-02-01 | 2013-04-24 | 北京市肿瘤防治研究所 | 存活素酶联免疫试剂盒及其应用 |
| EP2762159A1 (en) * | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
| DE102013012432A1 (de) * | 2013-07-29 | 2015-01-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immuntherapie von Prostatakrebs |
| WO2015066057A2 (en) * | 2013-10-28 | 2015-05-07 | Baylor College Of Medicine | Expansion of cmv-specific t cells from cmv-seronegative donors |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201321242D0 (en) * | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| ES2947818T3 (es) | 2014-11-18 | 2023-08-21 | Ascendis Pharma Endocrinology Div A/S | Nuevos profármacos poliméricos de la HCh |
| EP3220892B1 (en) | 2014-11-21 | 2021-10-13 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| IL260877B2 (en) * | 2015-03-27 | 2023-10-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| MY191654A (en) * | 2015-07-01 | 2022-07-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PT3319985T (pt) * | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| MY198087A (en) * | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| IL298653A (en) * | 2015-12-11 | 2023-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| SG11201804957VA (en) | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| RS65430B1 (sr) | 2016-03-16 | 2024-05-31 | Amal Therapeutics Sa | Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
| GB201609193D0 (en) * | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| KR20190037243A (ko) * | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
| WO2018055060A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| ES2946584T3 (es) | 2017-01-27 | 2023-07-21 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| SG11201907524UA (en) | 2017-03-03 | 2019-09-27 | Treos Bio Zrt | Peptide vaccines |
| BR112019028070A2 (pt) * | 2017-07-07 | 2020-07-14 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres |
| WO2019007974A1 (en) * | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| WO2019072871A2 (en) | 2017-10-09 | 2019-04-18 | Enterome S.A. | MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| CA3081436A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| WO2019104203A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| SI3773689T1 (sl) | 2018-04-11 | 2023-02-28 | Enterome S.A. | Antigenski peptidi za preprečevanje in zdravljenje raka |
| WO2019197563A2 (en) | 2018-04-11 | 2019-10-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
| JP7386852B2 (ja) * | 2018-05-15 | 2023-11-27 | インテルク ペプチド セラピューティクス リミテッド | ペプチド活性化剤 |
| US12134663B2 (en) | 2018-05-15 | 2024-11-05 | Interk Peptide Therapeutics Limited | Cationic peptides for activating Lck |
| CA3110760A1 (en) | 2018-09-04 | 2020-03-12 | Treos Bio Limited | Peptide vaccines |
| EP4045150A1 (en) | 2019-10-16 | 2022-08-24 | Enterome S.A. | Immunogenic compounds for treatment of adrenal cancer |
| FI4021487T3 (fi) | 2019-11-15 | 2024-02-06 | Enterome S A | Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon |
| MX2022012758A (es) * | 2020-04-14 | 2022-11-30 | Univ Montreal | Novedosos antigenos especificos de tumores para leucemia mieloide aguda (aml) y usos de estos. |
| JP2022144748A (ja) * | 2021-03-19 | 2022-10-03 | 日本電気株式会社 | 検査システム及び検査方法 |
| KR20240004764A (ko) | 2021-04-30 | 2024-01-11 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 mhc 발현을 위한 종양용해성 바이러스 |
| WO2023021056A1 (en) * | 2021-08-17 | 2023-02-23 | Intomics A/S | Vaccine design pipeline |
| EP4499678A1 (en) | 2022-03-31 | 2025-02-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (sl) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| EP0916678A3 (en) | 1993-06-03 | 1999-05-26 | Therapeutic Antibodies Inc. | Method of clotting blood |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ES2203782T3 (es) | 1996-01-17 | 2004-04-16 | Imperial College Innovations Limited | Inmunoterapia que utiliza linfocitos t citotoxicos (ctl). |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6420518B1 (en) * | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| US6255055B1 (en) * | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| US6274362B1 (en) * | 1999-02-04 | 2001-08-14 | Millennium Pharmaceuticals, Inc. | RGS-containing molecules and uses thereof |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| ATE472601T1 (de) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| WO2003042661A2 (en) * | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20050022239A1 (en) | 2001-12-13 | 2005-01-27 | Meuleman Petrus Gerardus | Recommending media content on a media system |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US20030223994A1 (en) | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| AU2003270311A1 (en) * | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US7811828B2 (en) * | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US8435507B2 (en) * | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| DE602005020047D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| FR2891462B1 (fr) * | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
| WO2007056511A2 (en) † | 2005-11-09 | 2007-05-18 | Ontherix, Inc. | Metal-binding therapeutic peptides |
| DK2567707T3 (en) * | 2007-07-27 | 2017-07-31 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| DE602008000891D1 (de) * | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
| RS53872B2 (sr) * | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
-
2008
- 2008-05-14 RS RS20150093A patent/RS53872B2/sr unknown
- 2008-05-14 ES ES08008944.4T patent/ES2532896T5/es active Active
- 2008-05-14 PT PT08008944T patent/PT2119726E/pt unknown
- 2008-05-14 EP EP08008944.4A patent/EP2119726B2/en active Active
- 2008-05-14 HU HUE08008944A patent/HUE024541T2/hu unknown
- 2008-05-14 DK DK08008944.4T patent/DK2119726T5/en active
- 2008-05-14 NO NO08008944A patent/NO2119726T3/no unknown
- 2008-05-14 PL PL08008944T patent/PL2119726T5/pl unknown
- 2008-05-14 SI SI200831406T patent/SI2119726T2/sl unknown
-
2009
- 2009-05-14 BR BR122019014468A patent/BR122019014468B8/pt not_active IP Right Cessation
- 2009-05-14 EA EA201071297A patent/EA019603B1/ru not_active IP Right Cessation
- 2009-05-14 US US12/466,222 patent/US8647629B2/en active Active
- 2009-05-14 PT PT97455703T patent/PT2291395E/pt unknown
- 2009-05-14 DK DK09745570.3T patent/DK2291395T4/en active
- 2009-05-14 AU AU2009248413A patent/AU2009248413B2/en not_active Ceased
- 2009-05-14 KR KR1020137008071A patent/KR101602024B1/ko active IP Right Grant
- 2009-05-14 HU HUE09745570A patent/HUE028102T2/en unknown
- 2009-05-14 SI SI200931275T patent/SI2291395T2/sl unknown
- 2009-05-14 CA CA2724198A patent/CA2724198C/en not_active Expired - Fee Related
- 2009-05-14 KR KR1020107027934A patent/KR101509284B1/ko active IP Right Grant
- 2009-05-14 ES ES09745570T patent/ES2549088T5/es active Active
- 2009-05-14 EP EP15154297.4A patent/EP2899206A1/en not_active Withdrawn
- 2009-05-14 WO PCT/EP2009/003447 patent/WO2009138236A1/en active Application Filing
- 2009-05-14 BR BRPI0912622A patent/BRPI0912622A2/pt not_active Application Discontinuation
- 2009-05-14 MX MX2010012443A patent/MX2010012443A/es active IP Right Grant
- 2009-05-14 JP JP2011508840A patent/JP5663473B2/ja not_active Expired - Fee Related
- 2009-05-14 NZ NZ588605A patent/NZ588605A/en not_active IP Right Cessation
- 2009-05-14 UA UAA201015020A patent/UA103481C2/ru unknown
- 2009-05-14 CN CN200980117564.0A patent/CN102027006B/zh not_active Expired - Fee Related
- 2009-05-14 EP EP09745570.3A patent/EP2291395B2/en active Active
- 2009-05-14 PL PL09745570T patent/PL2291395T5/pl unknown
-
2011
- 2011-06-03 HK HK11105597.3A patent/HK1156323A1/xx not_active IP Right Cessation
- 2011-06-03 HK HK15110277.6A patent/HK1209757A1/xx unknown
-
2012
- 2012-06-19 US US13/526,597 patent/US9498512B2/en active Active
-
2013
- 2013-03-15 US US13/841,442 patent/US20140086943A1/en not_active Abandoned
- 2013-06-28 US US13/931,413 patent/US10434136B2/en active Active
-
2015
- 2015-02-12 CY CY20151100138T patent/CY1115999T1/el unknown
- 2015-03-17 HR HRP20150300TT patent/HRP20150300T4/hr unknown
- 2015-10-14 CY CY20151100921T patent/CY1117171T1/el unknown
- 2015-10-27 HR HRP20151135TT patent/HRP20151135T4/hr unknown
-
2019
- 2019-07-12 US US16/510,442 patent/US11957729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2119726T2 (sl) | Novi in močni MHC peptidi razreda II, pridobljeni iz survivina in neurokana | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| PH12019502194A1 (en) | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | |
| JP4926231B2 (ja) | 二量体化ペプチド | |
| MY189042A (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| PH12018501933A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| HRP20161504T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga | |
| JP2011520436A5 (sl) | ||
| JP2012504393A5 (sl) | ||
| ATE461215T1 (de) | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden | |
| PH12018501892A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| WO2006037421A3 (en) | Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | |
| CN108728488A (zh) | 溶瘤病毒构建体、溶瘤病毒及其应用 | |
| AU2022204032B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| CN110713522A (zh) | 低pH插入肽的胞外段作为抗原的应用 | |
| WO2009123188A1 (ja) | ＭＨＣクラスＩＩ分子に提示されるサーバイビン（Ｓｕｒｖｉｖｉｎ）の部分ペプチドとその利用法 | |
| Bojarska et al. | Short Peptides as Powerful Arsenal for Smart Fighting Cancer | |
| MX2012006770A (es) | Peptidos tmem22 y vacunas que incluyen los mismos. | |
| JP6975716B2 (ja) | 樹状細胞標的化ペプチド、当該ペプチドを利用したペプチド融合体、及び当該ペプチド融合体を利用したワクチン | |
| HRP20211753T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| CN106519007B (zh) | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 | |
| AR106499A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón microcítico y otros tipos de cáncer | |
| AR105011A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia y métodos para crear soportes para el uso contra el cáncer de páncreas y otros tipos de cáncer |